Search

Protecting patents and maximizing their value are paramount to the success of brand pharmaceutical companies and university technology departments, in particular as they relate to generic competitors who file Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman Act. Saul Ewing’s...

Zoning, Land Development and Permitting Every real estate development project starts with a vision, but before construction can begin, land owners and developers must secure government approvals and satisfy neighbor and community concerns, a time-consuming and costly process. In addition, public...

In response to the ongoing challenges to their profits, pharmaceutical and other life sciences companies continue to outsource many specialized services. From R&D to manufacturing – and everything in between – opportunities abound for companies that have the knowledge and expertise to effectively...

Saul Ewing’s experienced patent attorneys assist companies and institutions in securing, leveraging, and enforcing commercially valuable intellectual property. From developing patent strategies on a global scale to vigorously asserting and defending patents in court, our team serves as trusted...

Industry-Specific, Business-Focused Legal Advice Increased pricing pressure combined with a rise in generic competition and continued regulatory uncertainty have squeezed the margins of life sciences companies. Helping navigate this ever-shifting terrain, Saul Ewing’s Life Sciences Practice consists...

Counsel From the Earliest Stage of Development Through Disposition of Projects Throughout the continuum of financing, acquiring, developing, leasing and selling real estate are a multitude of complexities to address and challenges to overcome—from regulatory hurdles and shifting capital stacks to...

Counsel From the Earliest Stage of Development Through Disposition of Projects Throughout the continuum of financing, acquiring, developing, leasing and selling real estate are a multitude of complexities to address and challenges to overcome—from regulatory hurdles and shifting capital stacks to...